These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19474784)

  • 1. QT as a safety biomarker in drug development.
    Whellan DJ; Green CL; Piccini JP; Krucoff MW
    Clin Pharmacol Ther; 2009 Jul; 86(1):101-4. PubMed ID: 19474784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
    Shah RR
    Pharmacol Ther; 2008 Aug; 119(2):215-21. PubMed ID: 18455801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
    Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
    Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A perspective on the use of concentration-QT modeling in drug development.
    Russell T; Riley SP; Cook JA; Lalonde RL
    J Clin Pharmacol; 2008 Jan; 48(1):9-12. PubMed ID: 18094215
    [No Abstract]   [Full Text] [Related]  

  • 6. Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates.
    Bloomfield D; Krishna R
    J Clin Pharmacol; 2008 Jan; 48(1):6-8. PubMed ID: 18094214
    [No Abstract]   [Full Text] [Related]  

  • 7. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.
    Garnett CE; Beasley N; Bhattaram VA; Jadhav PR; Madabushi R; Stockbridge N; Tornøe CW; Wang Y; Zhu H; Gobburu JV
    J Clin Pharmacol; 2008 Jan; 48(1):13-8. PubMed ID: 18094216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management.
    Fingert H; Varterasian M
    AAPS J; 2006 Mar; 8(1):E89-94. PubMed ID: 16584137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.
    Shah RR; Morganroth J; Kleiman RB
    Br J Clin Pharmacol; 2015 Mar; 79(3):456-64. PubMed ID: 25060671
    [No Abstract]   [Full Text] [Related]  

  • 11. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges of biomarkers in drug discovery and development.
    Goodsaid F
    Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates.
    Gwathmey JK; Tsaioun K; Hajjar RJ
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):647-60. PubMed ID: 19442031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone.
    Service JA; Waring WS
    Clin Toxicol (Phila); 2008 Jan; 46(1):71-3. PubMed ID: 18167038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic therapeutic peptides: science and market.
    Vlieghe P; Lisowski V; Martinez J; Khrestchatisky M
    Drug Discov Today; 2010 Jan; 15(1-2):40-56. PubMed ID: 19879957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of biochemical markers in development of drugs for treatment of osteoarthritis.
    Qvist P; Christiansen C; Karsdal MA; Madsen SH; Sondergaard BC; Bay-Jensen AC
    Biomarkers; 2010 Feb; 15(1):1-19. PubMed ID: 20085489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug development.
    Woodcock J
    Clin Pharmacol Ther; 2009 Jul; 86(1):12-4. PubMed ID: 19536116
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity.
    Shah RR
    Fundam Clin Pharmacol; 2002 Apr; 16(2):147-56. PubMed ID: 12031067
    [No Abstract]   [Full Text] [Related]  

  • 19. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
    Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of drug-related QT prolongation on FDA regulatory decisions.
    Park E; Willard J; Bi D; Fiszman M; Kozeli D; Koerner J
    Int J Cardiol; 2013 Oct; 168(5):4975-6. PubMed ID: 23920061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.